Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
A Novel Strategy for Enhance Potentiation of Meglumine Antimoniate Against Leishmania Major in Vitro Publisher



Mirzaei F1 ; Khanahmad H2 ; Namdar F3 ; Izadi S3 ; Hejazi SH4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Skin Diseases and Leishmaniasis Research Center, Department of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Iranian Journal of Parasitology Published:2019


Abstract

Background: We aimed to design a different method of drug delivery for increased transfer of the choice drug (meglumine antimoniate) within the host cells. Therefore, listeriolysin O (LLO), a bacterial product which is a member of pore-forming peptides was used as an enhancer factor with meglumine antimoniate in order to facilitate the transition of the drug across macrophage membrane. Methods: LLO was produced in Isfahan University of Medical Sciences in 2016, by expressing the hlyA gene in Escherichia coli and purified using affinity chromatography. Cytotoxicity of the purified protein was investigated in an in vitro model of macrophage Leishmania infection. Results: LLO was cytotoxic against murine macrophage cells (J774-A1) and amastigote forms of L. major (MRHO/IR/75/ER). It was less toxic to macrophages (CC50=2.56 μg ml-1 ±0.09) than to the parasites (IC50=1.72 μg ml-1 ±0.07). Moreover, non-cytotoxic concentration of LLO (0.006 ug ml-1) potentiated the cytotoxicity induced by low dose concentration of meglumine antimoniate. Very little dose of meglumine antimoniate was needed when combined with the LLO (IC50=12.63 μg ml-1 ±0.13) in comparison with the cytotoxicity induced when the drug is used alone (IC50=46.17 μg ml-1 ±0.28). Conclusion: The combination of pore-forming proteins with anti-leishmanial agents could increase the advantage of anti-leishmanial drugs. Since lower concentrations of anti-leishmanial drugs can reduce undesirable side effects of chemotherapy trials carried out in animal models and then in humans with this system. © 2019, Tehran University of Medical Sciences (TUMS). All rights reserved.
Related Docs
View other Related Docs
1. Anti-Leishmania Activity of Osthole, Pharmacognosy Research (2016)
2. P-Glycoprotein a Gene Expression in Glucantime-Resistant and Sensitive Leishmania Major (Mrho/Ir/75/Er), Iranian Journal of Parasitology (2014)
3. Evaluation of the Antileishmanial Effect of Polyclonal Antibodies and Cationic Antimicrobial Peptides, Pathogens and Global Health (2023)
4. The Role of Bax in the Apoptosis of Leishmania-Infected Macrophages, Microbial Pathogenesis (2020)
5. Review of the Prevalence and Causes of Antimony Compounds Resistance in Different Societies: Review Article, Tehran University Medical Journal (2017)
6. Chitosan-Titanium Dioxide-Glucantime Nanoassemblies Effects on Promastigote and Amastigote of Leishmania Major, International Journal of Biological Macromolecules (2018)
7. Ciprofloxacin Nano-Niosomes for Targeting Intracellular Infections: An in Vitro Evaluation, Journal of Nanoparticle Research (2013)
8. The Potential Role of Protein Disulfide Isomerases (Pdis) During Parasitic Infections: A Focus on Leishmania Spp., Pathogens and Disease (2023)
Experts (# of related papers)
View all Related Experts
Seyed Hossein Hejazi (16)
Sedighe Saberi (7)
Other Related Docs
9. Recombinant C-Reactive Protein: A Potential Candidate for the Treatment of Cutaneous Leishmaniasis of Balb/C Mice Caused by Leishmania Major, Acta Parasitologica (2021)
10. Therapeutic Effect of Topical Tamoxifen in Murine Cutaneous Leishmaniasis Caused by Leishmania Major, Antimicrobial Agents and Chemotherapy (2024)
11. Combinatorial Delivery of Antigen and Tlr Agonists Via Plga Nanoparticles Modulates Leishmania Major-Infected-Macrophages Activation, Biomedicine and Pharmacotherapy (2021)
12. Anti-Leishmanial Effects of Resveratrol and Resveratrol Nanoemulsion on Leishmania Major, BMC Microbiology (2022)
13. The Characterization and Antileishmanial Evaluation on Leishmania Major With Chitosan/Zno Bio-Nanocomposite As Drug Delivery Systems, Nanomedicine Research Journal (2022)
14. The Study of the Inhibitory Effects of Aqueous and Ethanolic Extracts of Ziziphora Tenuior L. on the Proliferation of Leishmania Major Amastigotes, Iranian Journal of Dermatology (2018)
15. Study of Therapeutic Effect of Different Concentrations of Imatinib on Balb/C Model of Cutaneous Leishmaniasis, AIMS Microbiology (2020)
16. Anti-Leishmaniasis Effect of Staphylococcus Aureus Protein a on the Size of the Lesion and Parasitic Load, Advanced Biomedical Research (2023)
17. Preparation and Evaluation of Clinical Effects of Glucantime Gel Mask, Journal of Isfahan Medical School (2013)
18. Evaluation of the Anti-Leishmanial Effect of Recombinant Clostridium Α-Toxin, Infection and Drug Resistance (2020)
19. Evaluation of Leishmanicidal Activity of Oxypeucedanin and Isoimperatorin on Leishmania Major Promastigotes, Journal of Isfahan Medical School (2013)
20. In Vitro Antileishmanial Activity of Falcaria Vulgaris Fractions on Leishmania Major, Jundishapur Journal of Natural Pharmaceutical Products (2017)
21. Butanol Fraction of Kelussia Odoratissima Mozaff Inhibits the Growth of Leishmania Major Promastigote and Amastigote, World's Veterinary Journal (2020)
22. Leishmanicidal Activities of Biosynthesized Baco3 (Witherite) Nanoparticles and Their Biocompatibility With Macrophages, Bioprocess and Biosystems Engineering (2021)
23. Antimonial Treatment Failure Rate in Patients With Cutaneous Leishmaniasis, Tehran University Medical Journal (2018)
24. Development of Liposomes Loaded With Anti-Leishmanial Drugs for the Treatment of Cutaneous Leishmaniasis, Journal of Liposome Research (2013)
25. Investigating in Vitro Anti-Leishmanial Effects of Silibinin and Silymarin on Leishmania Major, Annals of parasitology (2018)
26. Evaluation of Different Concentrations of Imatinib on the Viability of Leishmania Major: An in Vitro Study, Advanced Biomedical Research (2019)
27. Leishmanicidal Activity of Films Containing Paromomycin and Gentamicin Sulfate Both in Vitro and in Vivo, Iranian Journal of Parasitology (2011)
28. Targeting Mcf-7 Cell Line by Listeriolysin O Pore Forming Toxin Fusion With Ahnp Targeted Peptide, Advanced Biomedical Research (2019)
29. A Survey on Inhibitory Effect of Whole-Body Extraction and Secretions of Lucilia Sericata’S Larvae on Leishmania Major in Vitro, Advanced Biomedical Research (2020)
30. The Effects of Prednisolone and Mometasone on Wound Healing Caused by Leishmania Major in Balb/C Mice, Journal of Isfahan Medical School (2020)
31. Preparation and Characterization of Itraconazole Loaded Nanomicelles Based on Dextran–Behenic Acid for Cutaneous Leishmaniasis Treatment, Drug Development and Industrial Pharmacy (2021)
32. Ocular Parasitosis Caused by Protozoan Infection During Travel: Focus on Prevention and Treatment, International Journal of Preventive Medicine (2018)
33. Induction of Immune Responses by Dna Vaccines Formulated With Dendrimer and Poly (Methyl Methacrylate) (Pmma) Nano-Adjuvants in Balb/C Mice Infected With Leishmania Major, Open Access Macedonian Journal of Medical Sciences (2018)
34. Double-Walled Microspheres Loaded With Meglumine Antimoniate: Preparation, Characterization and in Vitro Release Study, Drug Development and Industrial Pharmacy (2014)
35. Effect of Peel and Leaf Extract of Walnut (Juglans Regia L.) on Cutaneous Leishmaniasis Caused by Leishmania Major in Balb/C Mice, Journal of Chemical and Pharmaceutical Sciences (2016)